Page:Ultomiris (ravulizumab-cwvz) injection (Corrected Supplement Approval).pdf/5

BLA 761108/S-021 Page 5 the assessment instruments and methodology with the following wording in bold capital letters at the top of the first page of the submission:


 * BLA 761108 REMS ASSESSMENT METHODOLOGY (insert concise description of content in bold capital letters, e.g., ASSESSMENT METHODOLOGY, PROTOCOL, SURVEY METHODOLOGIES, AUDIT PLAN, DRUG USE STUDY)

Prominently identify any submission containing the REMS assessments or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission as appropriate:


 * BLA 761108 REMS ASSESSMENT


 * or


 * NEW SUPPLEMENT FOR BLA 761108/ S-000 CHANGES BEING EFFECTED IN 30 DAYS PROPOSED MINOR REMS MODIFICATION


 * or


 * NEW SUPPLEMENT FOR BLA 761108/ S-000 PRIOR APPROVAL SUPPLEMENT PROPOSED MAJOR REMS MODIFICATION


 * or


 * NEW SUPPLEMENT FOR BLA 761108/ S-000 PRIOR APPROVAL SUPPLEMENT
 * PROPOSED REMS MODIFICATIONS DUE TO SAFETY LABELING CHANGES SUBMITTED IN SUPPLEMENT XXX


 * or


 * NEW SUPPLEMENT (NEW INDICATION FOR USE) FORBLA 761108/ S-000
 * REMS ASSESSMENT PROPOSED REMS MODIFICATION (if included)

Should you choose to submit a REMS revision, prominently identify the submission containing the REMS revisions with the following wording in bold capital letters at the top of the first page of the submission:


 * REMS REVISIONS FOR BLA 761108

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov